New Results
Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate
Danmei Su, Xinglin Li, Cui He, Xueqing Huang, Meilin Chen, Qiang Wang, Wenchang Qin, Ying Liang, Rong Xu, Jinhua Wu, Peiwen Luo, Xiaofang Yang, Yilan Zeng, Mei Luo, Dongxia Luo, David M Salisbury, Donna Ambrosino, George Siber, Ralf Clemens, Peng Liang, Joshua G. Liang
doi: https://doi.org/10.1101/2021.05.16.444369
Danmei Su
1Clover Biopharmaceuticals, Chengdu, China
Xinglin Li
1Clover Biopharmaceuticals, Chengdu, China
Cui He
1Clover Biopharmaceuticals, Chengdu, China
Xueqing Huang
1Clover Biopharmaceuticals, Chengdu, China
Meilin Chen
1Clover Biopharmaceuticals, Chengdu, China
Qiang Wang
1Clover Biopharmaceuticals, Chengdu, China
Wenchang Qin
1Clover Biopharmaceuticals, Chengdu, China
Ying Liang
1Clover Biopharmaceuticals, Chengdu, China
Rong Xu
1Clover Biopharmaceuticals, Chengdu, China
Jinhua Wu
1Clover Biopharmaceuticals, Chengdu, China
Peiwen Luo
1Clover Biopharmaceuticals, Chengdu, China
Xiaofang Yang
1Clover Biopharmaceuticals, Chengdu, China
Yilan Zeng
2Public Health Clinical Center of Chengdu, Chengdu, China
Mei Luo
2Public Health Clinical Center of Chengdu, Chengdu, China
Dongxia Luo
2Public Health Clinical Center of Chengdu, Chengdu, China
David M Salisbury
3Scientific Advisory Board, Clover Biopharmaceuticals, Chengdu, China
Donna Ambrosino
3Scientific Advisory Board, Clover Biopharmaceuticals, Chengdu, China
George Siber
3Scientific Advisory Board, Clover Biopharmaceuticals, Chengdu, China
Ralf Clemens
3Scientific Advisory Board, Clover Biopharmaceuticals, Chengdu, China
Peng Liang
1Clover Biopharmaceuticals, Chengdu, China
Joshua G. Liang
1Clover Biopharmaceuticals, Chengdu, China
Article usage
Posted May 17, 2021.
Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate
Danmei Su, Xinglin Li, Cui He, Xueqing Huang, Meilin Chen, Qiang Wang, Wenchang Qin, Ying Liang, Rong Xu, Jinhua Wu, Peiwen Luo, Xiaofang Yang, Yilan Zeng, Mei Luo, Dongxia Luo, David M Salisbury, Donna Ambrosino, George Siber, Ralf Clemens, Peng Liang, Joshua G. Liang
bioRxiv 2021.05.16.444369; doi: https://doi.org/10.1101/2021.05.16.444369
Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate
Danmei Su, Xinglin Li, Cui He, Xueqing Huang, Meilin Chen, Qiang Wang, Wenchang Qin, Ying Liang, Rong Xu, Jinhua Wu, Peiwen Luo, Xiaofang Yang, Yilan Zeng, Mei Luo, Dongxia Luo, David M Salisbury, Donna Ambrosino, George Siber, Ralf Clemens, Peng Liang, Joshua G. Liang
bioRxiv 2021.05.16.444369; doi: https://doi.org/10.1101/2021.05.16.444369
Subject Area
Subject Areas
- Biochemistry (11753)
- Bioengineering (8752)
- Bioinformatics (29201)
- Biophysics (14974)
- Cancer Biology (12100)
- Cell Biology (17413)
- Clinical Trials (138)
- Developmental Biology (9422)
- Ecology (14182)
- Epidemiology (2067)
- Evolutionary Biology (18309)
- Genetics (12245)
- Genomics (16804)
- Immunology (11869)
- Microbiology (28098)
- Molecular Biology (11596)
- Neuroscience (60975)
- Paleontology (451)
- Pathology (1871)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2886)
- Systems Biology (7340)
- Zoology (1651)